Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Dutalys

Dutalys
2010 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$489M LATEST DEAL AMOUNT
Description

Developer of human, bi-specific antibodies used in drugs. The company specializes in the discovery and development of bi-specific and monoclonal antibodies used in pharmaceutical and therapeutic drugs.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • Muthgasse 11/2
  • Vienna, 1190
  • Austria
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Dutalys’s full profile, request a free trial.

Dutalys Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 18-Dec-2014 $489M 00000 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Dutalys Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
INiTS Universit√§res Gr√ľnderservice Accelerator/Incubator 000 0000 000000 0

Dutalys Executive Team (2)

Name Title Board
Seat
Contact
Info
Roland Beckmann Ph.D Chief Scientific Officer and Co-Founder

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »